Forside  

Referansar

Vel data du ynskjer med i utskrifta
Tittel Versjon Status
IS-nr ISBN
Publiseringsdato
Utgjevar(e) Publikasjonstype
  • Norsk tittel - Nasjonal fagleg retningsline for utgreiing og behandling av bipolare lidingar
  • Engelsk tittel -
  • Versjon - 1
  • Status - Publisert
  • IS-nr - 1925
  • ISBN - 9788280812353
  • DOI -
  • Revisjonsdato -
  • Neste revisjon -
  • Publikasjonsdato - 12.12.2012
  • Utløpsdato -
  • Utgjevar(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer

      1.   Aarre TF. Stemningslidelser: kliniske retningslinjer for utredning og behandling. Oslo: Statens helsetilsyn; 2000. Utredningsserie 3-2000.

      2.   Nasjonale retningslinjer for diagnostisering og behandling av voksne med depresjon i primær- og spesialisthelsetjenesten. Oslo: Helsedirektoratet; 2009. Nasjonale faglige retningslinjer. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonale-retningslinjer-for-diagnostisering-og-behandling-av-voksne-med-depresjon-i-primer--og-spesialisthelsetjenesten/Publikasjoner/nasjonale-retningslinjer-for-diagnostisering-og-behandling-av-voksne-med-depresjon.pdf

      3.   ...og bedre skal det bli!: nasjonal strategi for kvalitetsforbedring i sosial- og helsetjenesten (2005-2015): til deg som leder og utøver. Oslo: Sosial- og helsedirektoratet; 2005. Veileder. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonal-strategi-for-kvalitetsforbedring-i-sosial--og-helsetjenesten-og-bedre-skal-det-bli-2005-2015/Publikasjoner/nasjonal-strategi-for-kvalitetsforbedring-i-sosial--og-helsetjenesten-og-bedre-skal-det-bli-2005-2015.pdf

      4.   International statistical classification of diseases and related health problems. 10 utg. Geneva: World Health Organization; 1992.

      5.   ICD-10 : psykiske lidelser og atferdsforstyrrelser : kliniske beskrivelser og diagnostiske retningslinjer. Oslo: Universitetsforlaget; 1999.

      6.   Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4. utg., text revision. Washington, DC: American Psychiatric Association; 2000.

      7.   Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64(2):161-74.

      8.   Morken G, Vaaler AE, Folden GE, Andreassen OA, Malt UF. Age at onset of first episode and time to treatment in in-patients with bipolar disorder. Br J Psychiatry 2009;194(6):559-60.

      9.   Larsson S, Lorentzen S, Mork E, Barrett EA, Steen NE, Lagerberg TV, et al. Age at onset of bipolar disorder in a Norwegian catchment area sample. J Affect Disord 2010;124(1-2):174-7.

    10.   Mantere O, Suominen K, Valtonen HM, Arvilommi P, Isometsa E. Only half of bipolar I and II patients report prodromal symptoms. J Affect Disord 2008;111(2-3):366-71.

    11.   Mantere O, Suominen K, Leppamaki S, Valtonen H, Arvilommi P, Isometsa E. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study (JoBS). Bipolar Disord 2004;6(5):395-405.

    12.   Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60(3):261-9.

    13.   Mantere O, Suominen K, Valtonen HM, Arvilommi P, Leppamaki S, Melartin T, et al. Differences in outcome of DSM-IV bipolar I and II disorders. Bipolar Disord 2008;10(3):413-25.

    14.   Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010;12(1):1-9.

    15.   Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-28.

    16.   Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry 2005;66(6):693-704.

    17.   Valtonen HM, Suominen K, Mantere O, Leppamaki S, Arvilommi P, Isometsa E. Suicidal behaviour during different phases of bipolar disorder. J Affect Disord 2007;97(1-3):101-7.

    18.   Ösby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58(9):844-50.

    19.   Merikangas KR, Herrell R, Swendsen J, Rossler W, Ajdacic-Gross V, Angst J. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry 2008;65(1):47-52.

    20.   Fazel S, Lichtenstein P, Grann M, Goodwin GM, Langstrom N. Bipolar disorder and violent crime: new evidence from population-based longitudinal studies and systematic review. Arch Gen Psychiatry 2010;67(9):931-8.

    21.   Simonsen C, Sundet K, Vaskinn A, Ueland T, Romm KL, Hellvin T, et al. Psychosocial function in schizophrenia and bipolar disorder: Relationship to neurocognition and clinical symptoms. J Int Neuropsychol Soc 2010;16(5):771-83.

    22.   Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67 Suppl 9:3-8.

    23.   Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord 2006;8(2):103-16.

    24.   Andersson S, Barder HE, Hellvin T, Lovdahl H, Malt UF. Neuropsychological and electrophysiological indices of neurocognitive dysfunction in bipolar II disorder. Bipolar Disord 2008;10(8):888-99.

    25.   Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105(3):164-72.

    26.   Bauer MS, Biswas K, Kilbourne AM. Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. Am J Psychiatry 2009;166(11):1244-50.

    27.   Yen CF, Chen CS, Ko CH, Yeh ML, Yang SJ, Yen JY, et al. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci 2005;59(4):403-9.

    28.   Colom F, Vieta E, Tacchi MJ, Sanchez-Moreno J, Scott J. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005;7(Suppl 5):24-31.

    29.   Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8(3):232-41.

    30.   Jamison KR, Akiskal HS. Medication compliance in patients with bipolar disorder. Psychiatr Clin North Am 1983;6(1):175-92.

    31.   Gaudiano BA, Miller IW. Patients' expectancies, the alliance in pharmacotherapy, and treatment outcomes in bipolar disorder. J Consult Clin Psychol 2006;74(4):671-6.

    32.   Strauss JL, Johnson SL. Role of treatment alliance in the clinical management of bipolar disorder: stronger alliances prospectively predict fewer manic symptoms. Psychiatry Res 2006;145(2-3):215-23.

    33.   Tsai SM, Chen C, Kuo C, Lee J, Lee H, Strakowski SM. 15-year outcome of treated bipolar disorder. J Affect Disord 2001;63(1-3):215-20.

    34.   Lew KH, Chang EY, Rajagopalan K, Knoth RL. The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface 2006;19(9):41-6.

    35.   Ellicott A, Hammen C, Gitlin M, Brown G, Jamison K. Life events and the course of bipolar disorder. Am J Psychiatry 1990;147(9):1194-8.

    36.   Miklowitz DJ. The Role of the Family in the Course and Treatment of Bipolar Disorder. Curr Dir Psychol Sci 2007;16(4):192-6.

    37.   Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987;144(2):201-4.

    38.   Boylan KR, Bieling PJ, Marriott M, Begin H, Young LT, MacQueen GM. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 2004;65(8):1106-13.

    39.   Henry C, Van den Bulke D, Bellivier F, Etain B, Rouillon F, Leboyer M. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry 2003;64(3):331-5.

    40.   Salloum IM, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000;2(3 Pt 2):269-80.

    41.   Kessing LV. The effect of comorbid alcoholism on recurrence in affective disorder: a case register study. J Affect Disord 1999;53(1):49-55.

    42.   Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Jr., et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007;64(1):57-64.

    43.   Kupka RW, Luckenbaugh DA, Post RM, Suppes T, Altshuler LL, Keck PE, Jr., et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005;162(7):1273-80.

    44.   Henquet C, Krabbendam L, de GR, ten HM, van OJ. Cannabis use and expression of mania in the general population. J Affect Disord 2006;95(1-3):103-10.

    45.   Dunayevich E, Sax KW, Keck PE, Jr., McElroy SL, Sorter MT, McConville BJ, et al. Twelve-month outcome in bipolar patients with and without personality disorders. J Clin Psychiatry 2000;61(2):134-9.

    46.   Bieling PJ, MacQueen GM, Marriot MJ, Robb JC, Begin H, Joffe RT, et al. Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms. Bipolar Disord 2003;5(1):14-21.

    47.   Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 2005;57(11):1467-73.

    48.   Kringlen E, Torgersen S, Cramer V. Mental illness in a rural area: a Norwegian psychiatric epidemiological study. Soc Psychiatry Psychiatr Epidemiol 2006;41(9):713-9.

    49.   Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64(5):543-52.

    50.   Kessler RC, Akiskal HS, Angst J, Guyer M, Hirschfeld RM, Merikangas KR, et al. Validity of the assessment of bipolar spectrum disorders in the WHO CIDI 3.0. J Affect Disord 2006;96(3):259-69.

    51.   Ormel J, Petukhova M, Chatterji S, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, et al. Disability and treatment of specific mental and physical disorders across the world. Br J Psychiatry 2008;192(5):368-75.

    52.   Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007;68(8):1237-45.

    53.   Post RM, Luckenbaugh DA, Leverich GS, Altshuler LL, Frye MA, Suppes T, et al. Incidence of childhood-onset bipolar illness in the USA and Europe. Br J Psychiatry 2008;192(2):150-1.

    54.   Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349(9063):1436-42.

    55.   Appraisal of guidelines for research & evaluation II: Agree II instrument. Hamilton, Ontario: The AGREE Next Steps Consortium; 2009. Tilgjengelig fra: http://www.agreetrust.org/index.aspx?o=1397.

    56.   Metodebok: for utarbeidelse av nasjonale retningslinjer. Oslo: Helsedirektoratet; 2009.

    57.   Sign 50: A guideline developer's handbook. Rev. utg. Edinburgh: Scottish Intercollegiate Guidelines Network; 2008. Tilgjengelig fra: http://www.sign.ac.uk/pdf/sign50.pdf.

    58.   Nortvedt MW, Jamtvedt G, Graverholt G, Reinar LM. Å arbeide og undervise kunnskapsbasert: en arbeidsbok for sykepleiere. Oslo: Norsk sykepleierforbund; 2007.

    59.   Council of Europe. Developing a methodology for drawing up guidelines on best medical practice: recommendation Rec(2001)13 and explanatory memorandum. Strasbourg: Council of Europe Publishing; 2002.

    60.   LOV 1999-07-02 nr 64: Lov om helsepersonell m.v. (helsepersonelloven).

    61.   LOV 1999-07-02 nr 61: Lov om spesialisthelsetjenesten m.m. (spesialisthelsetjenesteloven).

    62.   LOV-2011-06-24-30. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven).

    63.   LOV 1999-07-02 nr 63: Lov om pasientrettigheter (pasientrettighetsloven).

    64.   LOV 1999-07-02 nr 62: Lov om etablering og gjennomføring av psykisk helsevern (psykisk helsevernloven).

    65.   Sosial- og helsedepartementet. Om lov om etablering og gjennomføring av psykisk helsevern (psykiatriloven). Ot.prp. nr. 11 (1998-99).

    66.   FOR 1993-06-29 nr 577: Forskrift om meldeplikt for helseinstitusjoner m m etter vergemålslovgivningen.

    67.   LOV 1918-05-31 nr 04: Lov om avslutning av avtaler, om fuldmagt og om ugyldige viljeserklæringer (avtaleloven).

    68.   LOV 1969-06-13 nr 26: Lov om skadeserstatning [skadeserstatningsloven].

    69.   Regler og veiledning for utfylling av helseattest for førerkort m.v. Oslo: Helsedirektoratet; 2011. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/forerkort-regler-og-veiledning-for-utfylling-av-helseattest-for-forerkort/Publikasjoner/forerkort-regler-og-veiledning-for-utfylling-av-helseattest-for-forerkort.pdf.

    70.   Retningslinjer for fylkesmennene ved behandling av førerkortsaker. Oslo: Helsedirektoratet; 2011. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/retningslinjer-for-fylkesmennene-ved-behandling-av-forerkortsaker/Publikasjoner/veileder-forerkort.pdf.

    71.   FOR 2004-01-19 nr 298: Forskrift om førerkort m.m. (førerkortforskriften).

    72.   Hummelvoll JK. En helhetlig-eksistensiell psykiatrisk sykepleietilnærming i et lokalsamfunnsperspektiv. Klinisk sykepleie 2006;20(1):13-23.

    73.   Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2 utg. Oxford: Oxford University Press; 2007.

    74.   FOR 2004-12-23 nr 1837: Forskrift om individuell plan etter helselovgivningen og sosialtjenesteloven.

    75.   Individuell plan 2010: veileder til forskrift om individuell plan. rev utg. Oslo: Helsedirektoratet; 2010. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/individuell-plan-veileder-til-forskriften/Publikasjoner/individuell-plan-veileder-til-forskriften.pdf.

    76.   Barn som pårørende. Oslo: Helsedirektoratet; 2010. Rundskriv IS-5/2010. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/barn-som-parorende/Publikasjoner/barn-som-parorende.pdf

    77.   Beardslee WR, Versage EM, Gladstone TR. Children of affectively ill parents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1998;37(11):1134-41.

    78.   Lindgren T, Mathisen V. Diagnose bipolar lidelse: pasientens opplevelse: en fenomenologisk undersøkelse. Tromsø: [T. Lindgren]; 2000. Hovedoppgave (cand. psychol.) - Universitetet i Tromsø, 2000.

    79.   Karlsson B. Mani som fenomen og lidelse: pasient- og personalerfaringer som grunnlag for kunnskapsutvikling i psykiatrisk sykepleie. Oslo: Det medisinske fakultet, Institutt for sykepleievitenskapog helsefag, Universitetet i Oslo; 2004. Avhandling (dr.polit.).

    80.   Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J Clin Psychiatry 2008;69(11):1751-7.

    81.   Zimmerman M, Ruggero CJ, Chelminski I, Young D. Is bipolar disorder overdiagnosed? J Clin Psychiatry 2008;69(6):935-40.

    82.   Youngstrom E, Meyers O, Youngstrom JK, Calabrese JR, Findling RL. Diagnostic and measurement issues in the assessment of pediatric bipolar disorder: implications for understanding mood disorder across the life cycle. Dev Psychopathol 2006;18(4):989-1021.

    83.   Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002;47(2):125-34.

    84.   Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010;167(10):1194-201.

    85.   Kowatch RA, DelBello MP. Pharmacotherapy of children and adolescents with bipolar disorder. Psychiatr Clin North Am 2005;28(2):385-97.

    86.   Baroni A, Lunsford JR, Luckenbaugh DA, Towbin KE, Leibenluft E. Practitioner review: the assessment of bipolar disorder in children and adolescents. J Child Psychol Psychiatry 2009;50(3):203-15.

    87.   Sala R, Axelson D, Birmaher B. Phenomenology, longitudinal course, and outcome of children and adolescents with bipolar spectrum disorders. Child Adolesc Psychiatr Clin N Am 2009;18(2):273-89, vii.

    88.   Akiskal HS. Developmental pathways to bipolarity: are juvenile-onset depressions pre-bipolar? J Am Acad Child Adolesc Psychiatry 1995;34(6):754-63.

    89.   Akiskal HS, Akiskal KK, Lancrenon S, Hantouche EG, Fraud JP, Gury C, et al. Validating the bipolar spectrum in the French National EPIDEP Study: overview of the phenomenology and relative prevalence of its clinical prototypes. J Affect Disord 2006;96(3):197-205.

    90.   Wozniak J, Spencer T, Biederman J, Kwon A, Monuteaux M, Rettew J, et al. The clinical characteristics of unipolar vs. bipolar major depression in ADHD youth. J Affect Disord 2004;82 Suppl 1:S59-S69.

    91.   Chang K. Challenges in the diagnosis and treatment of pediatric bipolar depression. Dialogues Clin Neurosci 2009;11(1):73-80.

    92.   Birmaher B. Longitudinal course of pediatric bipolar disorder. Am J Psychiatry 2007;164(4):537-9.

    93.   Birmaher B, Axelson D. Course and outcome of bipolar spectrum disorder in children and adolescents: a review of the existing literature. Dev Psychopathol 2006;18(4):1023-35.

    94.   Geller B, Craney JL, Bolhofner K, DelBello MP, Williams M, Zimerman B. One-year recovery and relapse rates of children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry 2001;158(2):303-5.

    95.   Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004;55(9):875-81.

    96.   Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36(7):980-8.

    97.   Denicoff KD, Leverich GS, Nolen WA, Rush AJ, McElroy SL, Keck PE, et al. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med 2000;30(6):1391-7.

    98.   Malt UF, Andreassen OA, Melle I, Årsland D. Lærebok i psykiatri. 3 utg. Oslo: Gyldendal akademisk; 2012. Under publisering.

    99.   Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 2005;88(2):217-33.

  100.   Udal AH, Malt UF, Lovdahl H, Gjaerum B, Pripp AH, Groholt B. Motor function may differentiate attention deficit hyperactivity disorder from early onset bipolar disorder. Behav Brain Funct 2009;5:47.

  101.   McGoldrick M, Gerson R, Petry S. Genograms: assessment and intervention. 3 utg. New York: W.W. Norton & Company; 2008.

  102.   Poznanski EO, Cook SC, Carroll BJ. A depression rating scale for children. Pediatrics 1979;64(4):442-50.

  103.   Youngstrom EA, Gracious BL, Danielson CK, Findling RL, Calabrese J. Toward an integration of parent and clinician report on the Young Mania Rating Scale. J Affect Disord 2003;77(2):179-90.

  104.   Pavuluri MN, Henry DB, Devineni B, Carbray JA, Birmaher B. Child mania rating scale: development, reliability, and validity. J Am Acad Child Adolesc Psychiatry 2006;45(5):550-60.

  105.   Kupka RW, Luckenbaugh DA, Post RM, Leverich GS, Nolen WA. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003;64(12):1483-94.

  106.   Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2007;68(10):1472-9.

  107.   Tamam L, Karakus G, Ozpoyraz N. Comorbidity of adult attention-deficit hyperactivity disorder and bipolar disorder: prevalence and clinical correlates. Eur Arch Psychiatry Clin Neurosci 2008;258(7):385-93.

  108.   Joshi G, Wilens T. Comorbidity in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am 2009;18(2):291-319, vii-viii.

  109.   Klassen LJ, Katzman MA, Chokka P. Adult ADHD and its comorbidities, with a focus on bipolar disorder. J Affect Disord 2010;124(1-2):1-8.

  110.   Geller B, Zimerman B, Williams M, DelBello MP, Frazier J, Beringer L. Phenomenology of prepubertal and early adolescent bipolar disorder: examples of elated mood, grandiose behaviors, decreased need for sleep, racing thoughts and hypersexuality. J Child Adolesc Psychopharmacol 2002;12(1):3-9.

  111.   Rydén E, Thase ME, Straht D, Aberg-Wistedt A, Bejerot S, Landen M. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 2009;120(3):239-46.

  112.   Leibenluft E, Rich BA. Pediatric bipolar disorder. Annu Rev Clin Psychol 2008;4:163-87.

  113.   Mantere O, Melartin TK, Suominen K, Rytsala HJ, Valtonen HM, Arvilommi P, et al. Differences in Axis I and II comorbidity between bipolar I and II disorders and major depressive disorder. J Clin Psychiatry 2006;67(4):584-93.

  114.   McElroy SL, Altshuler LL, Suppes T, Keck PE, Jr., Frye MA, Denicoff KD, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158(3):420-6.

  115.   Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-8.

  116.   Grant BF, Hasin DS, Stinson FS, Dawson DA, Patricia CS, June RW, et al. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions. J Psychiatr Res 2005;39(1):1-9.

  117.   Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 2007;3:137-58.

  118.   Lunde AV, Fasmer OB, Akiskal KK, Akiskal HS, Oedegaard KJ. The relationship of bulimia and anorexia nervosa with bipolar disorder and its temperamental foundations. J Affect Disord 2009;115(3):309-14.

  119.   Gunderson JG, Weinberg I, Daversa MT, Kueppenbender KD, Zanarini MC, Shea MT, et al. Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry 2006;163(7):1173-8.

  120.   Goldstein BI, Levitt AJ. Further evidence for a developmental subtype of bipolar disorder defined by age at onset: results from the national epidemiologic survey on alcohol and related conditions. Am J Psychiatry 2006;163(9):1633-6.

  121.   Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7 Suppl 3:5-69.

  122.   Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006;68(5):684-91.

  123.   Low NC, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache 2003;43(9):940-9.

  124.   Perron BE, Howard MO, Nienhuis JK, Bauer MS, Woodward AT, Kilbourne AM. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2009;70(10):1407-15.

  125.   Laursen TM, Nordentoft M. Heart disease treatment and mortality in schizophrenia and bipolar disorder - changes in the Danish population between 1994 and 2006. J Psychiatr Res 2011;45(1):29-35.

  126.   Oedegaard KJ, Angst J, Neckelmann D, Fasmer OB. Migraine aura without headache compared to migraine with aura in patients with affective disorders. J Headache Pain 2005;6(5):378-86.

  127.   Fasmer OB, Akiskal HS, Hugdahl K, Oedegaard KJ. Non-right-handedness is associated with migraine and soft bipolarity in patients with mood disorders. J Affect Disord 2008;108(3):217-24.

  128.   Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008;10(5):607-16.

  129.   Fan AH, Hassell J. Bipolar disorder and comorbid personality psychopathology: a review of the literature. J Clin Psychiatry 2008;69(11):1794-803.

  130.   Comtois KA, Russo JE, Roy-Byrne P, Ries RK. Clinicians' assessments of bipolar disorder and substance abuse as predictors of suicidal behavior in acutely hospitalized psychiatric inpatients. Biol Psychiatry 2004;56(10):757-63.

  131.   Singh J, Mattoo SK, Sharan P, Basu D. Quality of life and its correlates in patients with dual diagnosis of bipolar affective disorder and substance dependence. Bipolar Disord 2005;7(2):187-91.

  132.   Nasjonale retningslinjer for forebygging av selvmord i psykisk helsevern. Oslo: Sosial- og helsedirektoratet; 2008. Nasjonale faglige retningslinjer. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonal-faglig-retningslinje-for-forebygging-av-selvmord-i-psykisk-helsevern/Publikasjoner/nasjonal-faglig-retningslinje-for-forebygging-av-selvmord-i-psykisk-helsevern.pdf

  133.   Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry 2007;20(1):17-22.

  134.   Kilbane EJ, Gokbayrak NS, Galynker I, Cohen L, Tross S. A review of panic and suicide in bipolar disorder: does comorbidity increase risk? J Affect Disord 2009;115(1-2):1-10.

  135.   Gray SM, Otto MW. Psychosocial approaches to suicide prevention: applications to patients with bipolar disorder. J Clin Psychiatry 2001;62 Suppl 25:56-64.

  136.   Rucci P, Frank E, Kostelnik B, Fagiolini A, Mallinger AG, Swartz HA, et al. Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy. Am J Psychiatry 2002;159(7):1160-4.

  137.   Davidson L, Rakfeldt J, Strauss J. The roots of the recovery movement in psychiatry: lessons learned. Chicester, UK; Hoboken, NJ: Wiley-Blackwell; 2010.

  138.   Simon GE, Ludman EJ, Unutzer J, Operskalski BH, Bauer MS. Severity of mood symptoms and work productivity in people treated for bipolar disorder. Bipolar Disord 2008;10(6):718-25.

  139.   LOV 1998-07-17 nr 61: Lov om grunnskolen og den vidaregåande opplæringa (opplæringslova).

  140.   Knudsen H. Sindslidende og arbejdsmarkedet. Socialpsykiatri 2000;3(2):1-23.

  141.   Knudsen H. JOBFORS: et praksisforskningsprojekt: foreløpig rapport. Århus: Psykiatrien i Århus amt, Center for evaluering; 2005.

  142.   McAlpine DD, Warner L. Barriers to Employment among Persons with Mental Illness: A Review of the Literature. New Brunswick, N.J: Center for Research on the Organization and Financing of Care for the Severely Mentally Ill, Institute for Health, Health Care Policy, and Aging Research, Rutgers University; 2000. Tilgjengelig fra: http://www.dri.illinois.edu/research/p01-04c/final_technical_report_p01-04c.pdf.

  143.   Rosenstock M, Tinggaard K, Holt H, Jensen S. Rummelighedens rammer: ansættelsesmuligheder for personer med hjerneskade, sindslidelse eller udviklingshæmning. København: Socialforskningsinstituttet; 2004. Socialforskningsinstituttet 04:22. Tilgjengelig fra: http://www.sfi.dk/graphics/SFI/Pdf/Rapporter/2004/0422_Rummeligheds_rammer.pdf

  144.   Bond GR. Supported employment: evidence for an evidence-based practice. Psychiatr Rehabil J 2004;27(4):345-59.

  145.   Arbeidsrettede tiltak for personer med psykiske problemer. Oslo: Sosial- og helsedirektoratet; 2005.

  146.   Schafft A. Å få seg en jobb: arbeidsrettet rehabilitering ved psykiske helseproblemer. Oslo: Kommuneforlaget; 2009.

  147.   Bond GR, Drake RE, Becker DR. Generalizability of the Individual Placement and Support (IPS) model of supported employment outside the US. World Psychiatry 2012;11(1):32-9.

  148.   Spjelkavik Ø, Frøyland K. Yrkeshemmede i det ordinære arbeidslivet : inkludering gjennom Arbeid med bistand. Oslo: Arbeidsforskningsinstituttet; 2003. AFIs rapportserie 3/2003.

  149.   Schafft A, Seierstad S, Helle KM. Arbeidsmarkedsetatens tilbud til personer med psykiske lidelser. Oslo: Arbeidsforskningsinstituttet; 1999. AFIs rapportserie 1/99.

  150.   Straughan H, Buckenham M. In-Sight: an evaluation of user-led, recovery-based, holistic group training for bipolar disorder. J Public Mental Health 2006;5(3):29-43.

  151.   Martinsen EW, Moser T, Borge L, Moe T, Johannessen B, Kaggestad J. Kropp og sinn: fysisk aktivitet og psykisk helse. Bergen: Fagbokforl.; 2004.

  152.   Skrede A, Munkvold H, Watne O, Martinsen EW. Treningskontaktar ved rusproblem og psykiske lidingar. Tidsskr Nor Lægeforen 2006;126(15):1925-7.

  153.   Frisklivssentraler [Nettdokument]. Oslo: Helsedirektoratet [oppdatert 27 Nov 2011; lest 17 Jul 2012]. Tilgjengelig fra: http://www.helsedirektoratet.no/folkehelse/frisklivssentraler/Sider/default.aspx

  154.   Fysisk aktivitet og psykisk helse: et tipshefte for helsepersonell om tilrettelegging og planlegging av fysisk aktivitet for mennesker med psykiske lidelser og problemer. Oslo: Helsedirektoratet; 2010. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/fysisk-aktivitet-og-psykisk-helse-et-tipshefte-for-helsepersonell-/Publikasjoner/fysisk-aktivitet-og-psykisk-helse-et-tipshefte-for-helsepersonell-.pdf.

  155.   Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002;63(5):384-90.

  156.   Solberg DK, Refsum H. Oppfølging av pasienter som bruker litium. Tidsskr Nor Lægeforen 2008;128(12):1410-2.

  157.   Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness. Efficacy, effectiveness and efficiency. Br J Psychiatry 1994;164(6):741-6.

  158.   Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001;55 Suppl 44:5-69.

  159.   Berk M, Berk L. Mood stabilizers and treatment adherence in bipolar disorder: addressing adverse events. Ann Clin Psychiatry 2003;15(3-4):217-24.

  160.   Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-42.

  161.   Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162(10):1805-19.

  162.   Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005;62(8):860-6.

  163.   Andreescu C, Mulsant BH, Emanuel JE. Complementary and alternative medicine in the treatment of bipolar disorder--a review of the evidence. J Affect Disord 2008;110(1-2):16-26.

  164.   Berg R, Smedslund G. Effekten av vitaminer, mineraler og andre kosttilskudd på psykiske symptomer hos personer med ADHD, angstlidelser, bipolar lidelse eller depresjon. Oslo: Nasjonalt kunnskapssenter for helsetjenesten; 2011. Rapport fra Kunnskapssenteret nr 03-2011. Tilgjengelig fra: http://www.kunnskapssenteret.no/Publikasjoner/11650.cms

  165.   Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial [see comments]. Arch Gen Psychiatry 1999;56(5):407-12.

  166.   Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006;188:46-50.

  167.   Keck PE, Jr., Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006;60(9):1020-2.

  168.   Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000;2(1):47-55.

  169.   Eden EA, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006;8(2):168-74.

  170.   Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163(2):210-6.

  171.   Potter M, Moses A, Wozniak J. Alternative treatments in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am 2009;18(2):483-514, xi.

  172.   Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 2008;108(1-2):49-58.

  173.   Fristad MA, Gavazzi SM, Mackinaw-Koons B. Family psychoeducation: an adjunctive intervention for children with bipolar disorder. Biol Psychiatry 2003;53(11):1000-8.

  174.   Pavuluri MN, Graczyk PA, Henry DB, Carbray JA, Heidenreich J, Miklowitz DJ. Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: development and preliminary results. J Am Acad Child Adolesc Psychiatry 2004;43(5):528-37.

  175.   Miklowitz DJ, George EL, Axelson DA, Kim EY, Birmaher B, Schneck C, et al. Family-focused treatment for adolescents with bipolar disorder. J Affect Disord 2004;82(Suppl 1):S113-S128.

  176.   Miklowitz DJ, Axelson DA, Birmaher B, George EL, Taylor DO, Schneck CD, et al. Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. Arch Gen Psychiatry 2008;65(9):1053-61.

  177.   Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999;318(7177):149-53.

  178.   Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60(4):402-7.

  179.   Simon GE, Ludman EJ, Unutzer J, Bauer MS, Operskalski B, Rutter C. Randomized trial of a population-based care program for people with bipolar disorder. Psychol Med 2005;35(1):13-24.

  180.   Reinares M, Colom F, Sanchez-Moreno J, Torrent C, Martinez-Aran A, Comes M, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord 2008;10(4):511-9.

  181.   Miller IW, Solomon DA, Ryan CE, Keitner GI. Does adjunctive family therapy enhance recovery from bipolar I mood episodes? J Affect Disord 2004;82(3):431-6.

  182.   Clarkin JF, Carpenter D, Hull J, Wilner P, Glick I. Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatr Serv 1998;49(4):531-3.

  183.   Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003;60(9):904-12.

  184.   Rea MM, Tompson MC, Miklowitz DJ, Goldstein MJ, Hwang S, Mintz J. Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol 2003;71(3):482-92.

  185.   Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007;64(4):419-26.

  186.   Kim EY, Miklowitz DJ. Expressed emotion as a predictor of outcome among bipolar patients undergoing family therapy. J Affect Disord 2004;82(3):343-52.

  187.   Miklowitz DJ, Axelson DA, George EL, Taylor DO, Schneck CD, Sullivan AE, et al. Expressed emotion moderates the effects of family-focused treatment for bipolar adolescents. J Am Acad Child Adolesc Psychiatry 2009;48(6):643-51.

  188.   Miller IW, Keitner GI, Ryan CE, Uebelacker LA, Johnson SL, Solomon DA. Family treatment for bipolar disorder: family impairment by treatment interactions. J Clin Psychiatry 2008;69(5):732-40.

  189.   West AE, Jacobs RH, Westerholm R, Lee A, Carbray J, Heidenreich J, et al. Child and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: pilot study of group treatment format. J Can Acad Child Adolesc Psychiatry 2009;18(3):239-46.

  190.   Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006;188:313-20.

  191.   Lam DH, Hayward P, Watkins ER, Wright K, Sham P. Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry 2005;162(2):324-9.

  192.   Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiatry 2006;67(2):277-86.

  193.   Williams JM, Alatiq Y, Crane C, Barnhofer T, Fennell MJ, Duggan DS, et al. Mindfulness-based Cognitive Therapy (MBCT) in bipolar disorder: preliminary evaluation of immediate effects on between-episode functioning. J Affect Disord 2008;107(1-3):275-9.

  194.   Cochran SD. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol 1984;52(5):873-8.

  195.   Zaretsky A, Lancee W, Miller C, Harris A, Parikh SV. Is cognitive-behavioural therapy more effective than psychoeducation in bipolar disorder? Can J Psychiatry 2008;53(7):441-8.

  196.   Klerman GL, Weissman MM, Rounsaville BJ. Interpersonal psychotherapy of depression: a brief, focues specific strategy. Northvale, N.J. ; London: J. Aronson; 1995.

  197.   Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005;62(9):996-1004.

  198.   Frank E. Treating bipolar disorder: a clinician's guide to interpersonal and social rhythm therapy. New York: Guilford Press; 2005.

  199.   Hlastala SA, Kotler JS, McClellan JM, McCauley EA. Interpersonal and social rhythm therapy for adolescents with bipolar disorder: treatment development and results from an open trial. Depress Anxiety 2010;27(5):457-64.

  200.   Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004;161(12):2222-9.

  201.   Nasjonal faglig retningslinje for utredning, behandling og oppfølging av personer med samtidig rus - og psykisk lidelse - ROP lidelser. rev utg. Oslo: Helsedirektoratet; 2012. Tilgjengelig fra: http://helsedirektoratet.no/publikasjoner/nasjonal-faglig-retningslinje-personer-med-rop-lidelser/Publikasjoner/nasjonal-faglig-retningslinje-personer-med-rop-lidelser.pdf.

  202.   Sheehan DV, Lecrubier Y. Mini International Neuropsychiatric Interview (MINI). Tampa/Paris: University of South Florida Institute for Research in Psychiatry/INSERM-Hôpital de la Salpetriere; 1994.

  203.   Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993;88(6):791-804.

  204.   Albanese MJ, Pies R. The bipolar patient with comorbid substance use disorder: recognition and management. CNS Drugs 2004;18(9):585-96.

  205.   Drake RE, Xie H, McHugo GJ, Shumway M. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders. Biol Psychiatry 2004;56(10):749-56.

  206.   Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 2007;164(1):100-7.

  207.   Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005;62(1):37-45.

  208.   Hegerl U, Himmerich H, Engmann B, Hensch T. Mania and attention-deficit/hyperactivity disorder: common symptomatology, common pathophysiology and common treatment? Curr Opin Psychiatry 2010;23(1):1-7.

  209.   Galanter CA, Leibenluft E. Frontiers between attention deficit hyperactivity disorder and bipolar disorder. Child Adolesc Psychiatr Clin N Am 2008;17(2):325-46.

  210.   Aarre TF, Dahl AA. Pharmacotherapy for bipolar depression: a review of the evidence. Current Psychiatry Reviews 2008;4(3):145-56.

  211.   Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008;69(10):1589-601.

  212.   Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7):1351-60.

  213.   Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26(6):600-9.

  214.   McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71(2):163-74.

  215.   Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62.

  216.   DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009;11(5):483-93.

  217.   Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88.

  218.   Brown ES, Perantie DC, Dhanani N, Beard L, Orsulak P, Rush AJ. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord 2006;93(1-3):219-22.

  219.   Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 2009;70(2):247-58.

  220.   Thase ME. Maintenance therapy for bipolar disorder. J Clin Psychiatry 2008;69(11):e32.

  221.   Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004;65(12):1715-9.

  222.   McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, Kennedy SH. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Pharmacol 2004;11(2):e218-e226.

  223.   Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del ZM. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 1993;88(6):434-9.

  224.   Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008;10(2):323-33.

  225.   Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194(1):4-9.

  226.   Nolen WA, Kupka RW, Hellemann G, Frye MA, Altshuler LL, Leverich GS, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 2007;115(5):360-5.

  227.   van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(2):223-31.

  228.   Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85(3):259-66.

  229.   Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007;68(12):1840-4.

  230.   Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157(1):124-6.

  231.   Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6(3):213-23.

  232.   Zhang ZJ, Kang WH, Tan QR, Li Q, Gao CG, Zhang FG, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007;41(3-4):360-9.

  233.   McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002;4(3):207-13.

  234.   Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006;45(3):298-304.

  235.   Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr Scand 2010;121(3):201-8.

  236.   Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4(4):313-22.

  237.   Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E. The use of antidepressants in bipolar disorder. J Clin Psychiatry 2008;69(8):1307-18.

  238.   Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148(7):910-6.

  239.   Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158(6):906-12.

  240.   Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164(4):549-50.

  241.   Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356(17):1711-22.

  242.   Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Jr., et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163(2):232-9.

  243.   Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63(6):508-12.

  244.   Biederman J, Mick E, Spencer TJ, Wilens TE, Faraone SV. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 2000;10(3):185-92.

  245.   Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord 2004;82(1):149-58.

  246.   Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: National Institute for Health and Clinical Excellence; 2006. National Clinical Practice Guideline Number 38. Tilgjengelig fra: http://guidance.nice.org.uk/CG38/Guidance

  247.   Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8(6):721-39.

  248.   Suppes T, Marangell LB, Bernstein IH, Kelly DI, Fischer EG, Zboyan HA, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008;111(2-3):334-43.

  249.   Patel NC, DelBello MP, Bryan HS, Adler CM, Kowatch RA, Stanford K, et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006;45(3):289-97.

  250.   Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161(3):564-6.

  251.   Zarate CA, Jr., Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56(1):54-60.

  252.   Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE, Jr., Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164(8):1242-9.

  253.   Fink M. Convulsive therapy: a review of the first 55 years. J Affect Disord 2001;63(1-3):1-15.

  254.   UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361(9360):799-808.

  255.   Moksnes KM. Relapse following electroconvulsive therapy. Tidsskr Nor Laegeforen 2011;131(20):1991-3.

  256.   Rose D, Fleischmann P, Wykes T, Leese M, Bindman J. Patients' perspectives on electroconvulsive therapy: systematic review. BMJ 2003;326(7403):1363.

  257.   Ingram A, Saling MM, Schweitzer I. Cognitive side effects of brief pulse electroconvulsive therapy: a review. J ECT 2008;24(1):3-9.

  258.   Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109(3):251-63.

  259.   Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54(1):37-42.

  260.   Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204.

  261.   Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48(10):915-21.

  262.   Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990;23(3):143-50.

  263.   Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21(3):176-80.

  264.   Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111-21.

  265.   Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 2008;105(1-3):101-8.

  266.   Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975;32(1):34-42.

  267.   Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37(2):171-8.

  268.   Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Lithium treatment of acute mania in adolescents: a large open trial. J Am Acad Child Adolesc Psychiatry 2003;42(9):1038-45.

  269.   Kafantaris V, Coletti DJ, Dicker R, Padula G, Pleak RR, Alvir JM. Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry 2004;43(8):984-93.

  270.   Findling RL, McNamara NK, Stansbrey R, Gracious BL, Whipkey RE, Demeter CA, et al. Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization. J Am Acad Child Adolesc Psychiatry 2006;45(2):142-8.

  271.   Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry 2001;40(12):1448-56.

  272.   Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159(7):1146-54.

  273.   Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194(1):40-8.

  274.   Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63(12):1148-55.

  275.   Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159(6):1011-7.

  276.   DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006;45(3):305-13.

  277.   Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 2008;69(11):1776-89.

  278.   Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008;192(2):135-43.

  279.   Pavuluri MN, Henry DB, Findling RL, Parnes S, Carbray JA, Mohammed T, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010;12(6):593-605.

  280.   McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007;46(1):107-25.

  281.   Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007;9(6):551-60.

  282.   Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65(4):478-84.

  283.   Weisler RH, Keck PE, Jr., Swann AC, Cutler AJ, Ketter TA, Kalali AH. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005;66(3):323-30.

  284.   Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000;12(1):5-10.

  285.   Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2(3 Pt 2):249-55.

  286.   Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8(1):15-27.

  287.   Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Divalproex Extended-Release in the Treatment of Bipolar Disorder in Children and Adolescents. J Am Acad Child Adolesc Psychiatry 2009;48(5):519-32.

  288.   DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41(10):1216-23.

  289.   Pavuluri MN, Henry DB, Carbray JA, Sampson G, Naylor MW, Janicak PG. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 2004;82 Suppl 1:S103-S111.

  290.   Biederman J, Joshi G, Mick E, Doyle R, Georgiopoulos A, Hammerness P, et al. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 2010;16(2):91-102.

  291.   Garza-Trevino ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. Am J Psychiatry 1992;149(1):121-2.

  292.   Janicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155(7):972-3.

  293.   Edwards R, Stephenson U, Flewett T. Clonazepam in acute mania: a double blind trial. Aust N Z J Psychiatry 1991;25(2):238-42.

  294.   Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006;8(5 Pt 1):485-9.

  295.   Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69(8):1237-45.

  296.   Bauer MS, McBride L, Williford WO, Glick H, Kinosian B, Altshuler L, et al. Collaborative care for bipolar disorder: Part II. Impact on clinical outcome, function, and costs. Psychiatr Serv 2006;57(7):937-45.

  297.   Larsen JK, Porsdal V, Aarre TF, Koponen HJ, Aarnio J, Kleivenes OK. Mania in the Nordic countries: patients and treatment in the acute phase of the EMBLEM study. Nord J Psychiatry 2009;63(4):285-91.

  298.   Rosa AR, Cruz N, Franco C, Haro JM, Bertsch J, Reed C, et al. Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin Psychiatry 2010;71(8):1000-6.

  299.   Muralidharan S, Fenton M. Containment strategies for people with serious mental illness. Cochrane Database Syst Rev 2006;3:CD002084.

  300.   Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH, et al. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988;45(8):727-32.

  301.   McElroy SL, Martens BE, Creech RS, Welge JA, Jefferson L, Guerdjikova AI, et al. Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. J Clin Psychiatry 2010;71(5):557-65.

  302.   McElroy SL, Martens BE, Winstanley EL, Creech R, Malhotra S, Keck PE, Jr. Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. J Affect Disord 2010;124(1-2):157-63.

  303.   Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970;2(7668):326-30.

  304.   Stallone F, Shelley E, Mendlewicz J, Fieve RR. The use of lithium in affective disorders. 3. A double-blind study of prophylaxis in bipolar illness. Am J Psychiatry 1973;130(9):1006-10.

  305.   Prien RF, Caffey EM, Jr., Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973;28(3):337-41.

  306.   Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161(2):217-22.

  307.   Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58(11):470-8.

  308.   Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000;42 Suppl 1:2-10.

  309.   Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986;47(10):490-4.

  310.   Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64(2):144-51.

  311.   Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65(3):432-41.

  312.   Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57(5):481-9.

  313.   Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44(5):409-17.

  314.   Revicki DA, Hirschfeld RM, Ahearn EP, Weisler RH, Palmer C, Keck PE, Jr. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. J Affect Disord 2005;86(2-3):183-93.

  315.   Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162(7):1281-90.

  316.   Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45.

  317.   Pavuluri MN, Henry DB, Carbray JA, Sampson GA, Naylor MW, Janicak PG. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol 2006;16(3):336-50.

  318.   Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-5.

  319.   Zarate CA, Jr., Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161(1):169-71.

  320.   Ahlfors UG, Baastrup PC, Dencker SJ, Elgen K, Lingjaerde O, Pedersen V, et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981;64(3):226-37.

  321.   Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263-71.

  322.   Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163(2):247-56.

  323.   Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166(4):476-88.

  324.   Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011;72(11):1452-64.

  325.   Keck PE, Jr., Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67(4):626-37.

  326.   Keck PE, Jr., Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68(10):1480-91.

  327.   Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999;14(5):283-5.

  328.   Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60(4):392-400.

  329.   Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64(9):1013-24.

  330.   Pavuluri MN, Henry DB, Moss M, Mohammed T, Carbray JA, Sweeney JA. Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009;19(1):75-82.

  331.   Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008;118(5):347-56.

  332.   Quitkin FM, Kane J, Rifkin A, Ramos-Lorenzi JR, Nayak DV. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Arch Gen Psychiatry 1981;38(8):902-7.

  333.   Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41(11):1096-104.

  334.   FOR-2006-12-15-1423. Forskrift om bruk av skjerming i institusjoner i det psykiske helsevernet.

  335.   Norvoll R. Det lukkede rom: bruk av skjerming som behandling og kontroll i psykiatriske akuttposter. Oslo: Institutt for sosiologi og samfunnsgeografi, Det samfunnsvitenskapelige fakultet, Universitetet i Oslo Unipub; 2007. Series of dissertations submitted to the Faculty of Social Sciences, University of Oslo no. 64. Avhandling (dr.polit.).

  336.   Vedrørende utskrivning av pasienter fra døgnopphold i psykisk helsevern. Oslo: Sosial- og helsedirektoratet; 2004. Rundskriv IS-17/2004. Tilgjengelig fra: http://www.helsedirektoratet.no/publikasjoner/vedrorende-utskrivning-av-pasienter-fra-dognopphold-i-psykisk-helsevern/Publikasjoner/vedrorende-utskrivning-av-pasienter-fra-dognopphold-i-psykisk-helsevern.pdf

  337.   Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157(2):179-84.

  338.   Berle JO, Solberg DK, Spigset O. Behandling av bipolar lidelse under svangerskap og fødsel. Tidsskr Nor Lægeforen 2011;131(2):126-9.

  339.   Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011;24(1):34-40.

  340.   Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010;167(8):892-7.

  341.   Webb RT, Howard L, Abel KM. Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst Rev 2004;(2):CD004411.

  342.   Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol 2010;6(6):689-99.

  343.   Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79(4):301-8.

  344.   Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16(10):1075-85.

  345.   Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di GE, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66(5):695-705.

  346.   Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40(10):1723-33.

  347.   Greene MF. Teratogenicity of SSRIs--serious concern or much ado about little? N Engl J Med 2007;356(26):2732-3.

  348.   Pharmacovigilance Working Party. SSRIs, venlafaxine and mirtazapine and the risk of Persistent Pulmonary Hypertension in Neonates (PPHN): final SPC and PL wording agreed by the PhVWP in March 2010. [s.l]: Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human, CMDh; 2010. CMDh/PhVWP/019/2010. Tilgjengelig fra: http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Product_Information/PhVWP_Recommendations/SSRIs__venlafaxine_and_mirtazapine/CMDhPhVWP0192010_March10.pdf

  349.   Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356(26):2684-92.

  350.   Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356(26):2675-83.

  351.   Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354(6):579-87.

  352.   Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17(8):801-6.

  353.   Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293(19):2372-83.

  354.   Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 8 utg. Philadelphia: Lippincott Williams & Wilkins; 2008.

  355.   Schaefer C, Peters P, Miller RK, red. Drugs during pregnancy and lactation: treatment options and risk assessment. Amsterdam: Elsevier; 2007.

  356.   Schou M, Goldfield MD, Weinstein MR, Villeneuve A. Lithium and pregnancy. I. Report from the Register of Lithium Babies. Br Med J 1973;2(5859):135-6.

  357.   Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271(2):146-50.

  358.   Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci 2008;45(2):95-106.

  359.   Attenhofer Jost CH, Connolly HM, Dearani JA, Edwards WD, Danielson GK. Ebstein's Anomaly. Circulation 2007;115(2):277-85.

  360.   Galbally M, Roberts M, Buist A. Mood stabilizers in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44(11):967-77.

  361.   Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998;59 Suppl 2:18-28.

  362.   Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997;54(1):9-13.

  363.   Shor S, Koren G, Nulman I. Teratogenicity of lamotrigine. Can Fam Physician 2007;53(6):1007-9.

  364.   Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70(22 Pt 2):2152-8.

  365.   Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008;71(10):714-22.

  366.   Meador KJ, Penovich P. What is the risk of orofacial clefts from lamotrigine exposure during pregnancy? Neurology 2008;71(10):706-7.

  367.   Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium. J Clin Psychiatry 2010;71(5):649-50.

  368.   Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362(23):2185-93.

  369.   Valproic acid: long-term effects on children exposed in utero. Prescrire Int 2009;18(104):253-7.

  370.   Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360(16):1597-605.

  371.   Bromley RL, Mawer G, Love J, Kelly J, Purdy L, McEwan L, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010;51(10):2058-65.

  372.   Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16(1):9-17.

  373.   Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28(3):279-88.

  374.   Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15(3):183-92.

  375.   McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66(4):444-9.

  376.   Coppola D, Russo LJ, Kwarta RF, Jr., Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007;30(3):247-64.

  377.   Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008;192(5):333-7.

  378.   Berle JO, Steen VM, Aamo TO, Breilid H, Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004;65(9):1228-34.

  379.   Moretti ME, Koren G, Verjee Z, Ito S. Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. Ther Drug Monit 2003;25(3):364-6.

  380.   Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-89.

  381.   Page-Sharp M, Kristensen JH, Hackett LP, Beran RG, Rampono J, Hale TW, et al. Transfer of lamotrigine into breast milk. Ann Pharmacother 2006;40(7-8):1470-1.

  382.   Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. J Clin Psychopharmacol 1998;18(2):167-9.

  383.   Croke S, Buist A, Hackett LP, Ilett KF, Norman TR, Burrows GD. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 2002;5(3):243-7.

  384.   Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. Am J Psychiatry 2004;161(9):1715-6.

  385.   Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med 1998;28(1):81-91.

  386.   Aziz R, Lorberg B, Tampi RR. Treatments for late-life bipolar disorder. Am J Geriatr Pharmacother 2006;4(4):347-64.

  387.   Gebretsadik M, Jayaprabhu S, Grossberg GT. Mood disorders in the elderly. Med Clin North Am 2006;90(5):789-805.

  388.   Young RC, Gyulai L, Mulsant BH, Flint A, Beyer JL, Shulman KI, et al. Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry 2004;12(4):342-57.

  389.   Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging 2005;22(1):39-54.

  390.   Depp CA, Lindamer LA, Folsom DP, Gilmer T, Hough RL, Garcia P, et al. Differences in clinical features and mental health service use in bipolar disorder across the lifespan. Am J Geriatr Psychiatry 2005;13(4):290-8.

  391.   Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161(9):1537-47.

  392.   Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-Term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22(9):1068-84.

  393.   McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999;60(5):292-8.

  394.   Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol 2000;13(1):28-32.

  395.   Geddes JR, Briess D. Bipolar disorder [webdokument]. Clinical Evidence. BMJ Publishing Group [oppdatert 1 Aug 2007; lest 1 Mar 2011]. Tilgjengelig fra: http://clinicalevidence.bmj.com/ceweb/conditions/meh/1014/1014.jsp

  396.   Roose SP, Bone S, Haidorfer C, Dunner DL, Fieve RR. Lithium treatment in older patients. Am J Psychiatry 1979;136(6):843-4.

  397.   Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11(3):225-55.

  398.   Post RM. Bipolar disorder in adults: Maintenance treatment [webdokument]. Up To Date. UpToDate Inc [oppdatert 30 Jul 2012; lest 31 Aug 2012]. Tilgjengelig fra: http://www.uptodate.com/contents/bipolar-disorder-in-adults-maintenance-treatment

  399.   Eknes J, Løkke JA, Bakken TL, Mæhle I, red. Utredning og diagnostisering: utviklingshemning, psykiske lidelser og atferdsvansker. Oslo: Universitetsforlaget; 2008.

  400.   Løvdahl H, Andersson S, Hynnekleiv T, Malt UF. The phenomenology of recurrent brief depression with and without hypomanic features. J Affect Disord 2009;112(1-3):151-64.

  401.   LOV 1927-04-22 nr 03: Lov om vergemål for umyndige (vergemålsloven).

  402.   Dom 24. oktober 1995 i l.nr. 141B/1995: DnB Boligkreditt AS (advokat Håvard Holm - til prøve) mot A (advokat Cato Schiøtz). Norsk Retstidende 1995;160(25):1540-9.